May Health, a medical device company dedicated to helping women living with polycystic ovary syndrome (PCOS), announced that it raised €10 million ($11.7M) with participation from current investors, including Sofinnova Partners, Trill Impact, and Bpifrance, as well as new investor Nexpring Health™. Nexpring Health is a global leader in assisted reproductive technologies (ART) solutions, focused on advancing the future of fertility care. The company will use funds from this raise to drive completion of its pivotal U.S. Investigational Device Exemption (IDE) trial, REBALANCE, and will also support launch planning in Europe for the company’s Anavi™ System, which received CE Mark certification under the European Union’s Medical Device Regulation (EU MDR) in October 2025.
Related: SS Innovations closes $18.6M private placement
Affecting 10-13% of women worldwide, PCOS is the most common endocrine condition among reproductive-aged women and a leading cause of female infertility.1,2 Women with PCOS-related infertility often struggle to become pregnant because they are unable to ovulate consistently or at all.3
May Health’s Anavi System enables a one-time, office-based procedure intended to restore ovulation in women with PCOS-related infertility who do not respond to, are contraindicated to, or decline first-line therapies. The company is advancing development of this novel treatment approach in the U.S. under its REBALANCE pivotal IDE trial in eligible women with PCOS-related infertility. The study is designed to support submission to the U.S. Food and Drug Administration (FDA) for marketing authorization.
“For too long, women with PCOS-related infertility have needed more options to support their family-building journey,” said Colby Holtshouse, President and Chief Executive Officer of May Health. “With the continued support of our existing investors, we are making significant progress enrolling the REBALANCE trial and preparing to bring the Anavi System to market in Europe and the United States. We are pleased to welcome Nexpring Health to the syndicate, and we celebrate the strong mission alignment between our organizations.”
“May Health is addressing a critical gap in modern infertility care,” said Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners. “By targeting the underlying drivers of PCOS-related infertility, the company is reshaping the treatment paradigm for millions of women worldwide. We are proud to support a world-class team advancing meaningful progress in women’s healthcare.”
“At Nexpring Health, we believe our role as a global leader in ART solutions goes beyond the products we make. It’s about advancing fertility care in every way we can, for the clinicians on the front lines, for the embryologists working tirelessly in the lab, and ultimately, for the patients whose hopes and dreams depend on this progress,” said Wil Boren, Chief Executive Officer of Nexpring Health. “May Health is doing exactly the kind of work that can change patient outcomes, expand clinical options, and move this field forward, and we are proud to stand with them.”
